**📅 Date:** ➤ ⌈ [[2025-08-17-Sun〚Out-Licensing〛]]⌋ **💭 What:** ➤ Out-Licensing 能實現資源最佳分配，延長研發資金週期，並提高研發管線曝光度。 ➤ 作為投資人：它能帶來估值提升，而不會造成股權稀釋，並支持資本效率型的擴張 ⇩ 🅻🅸🅽🅺🆂 ⇩ **🏷️ Tags**: #💰/Investment **🗂 Menu**: ⌈[[✢ M O C ➣ 08 ⌈A U G - 2 0 2 5⌉ ✢|2025 - A U G - MOC]]⌋ ⌈[[✢ L O G ➢ 08 ⌈A U G - 2 0 2 5⌉ ✢|2025 - A U G - LOG]] ⌋ #👾/Private ➤ ⌈[[💰 NewCo]]⌋ --- **Out-Licensing** is a powerful tool to monetise innovation, access global markets, and de-risk pipeline assets without building full commercialisation infrastructure. --- ### 📘 Definition **Out-Licensing** refers to the process in which a company (**Licensor**) grants another party (**Licensee**) the **rights to develop, manufacture, market, or sell** a product, asset, or technology — often in exchange for: - **Upfront payment** - **Milestone payments** (clinical, regulatory, commercial) - **Royalties** on future sales --- ### 🧩 Typical Use Cases in Biotech |**Use Case**|**Strategic Benefit**| |---|---| |🔬 Early-stage biotech out-licenses a compound to big pharma|Gains non-dilutive funding + global development partner| |🌍 Regional out-licensing (e.g. China, EU)|Accesses local markets without infrastructure| |🧪 Platform tech licensing (e.g. LNP, delivery systems)|Monetizes enabling tech via multiple partners| |💊 Asset de-prioritization|Recoups value from shelved or non-core assets| --- ### 🎯 Strategic Advantages - 💸 **Non-dilutive capital**: - Upfronts and milestones fund core programs - 🤝 **Strategic partnerships**: - Tap into partner’s regulatory, clinical, or commercial muscle - 🧩 **Focus retention**: - Company can prioritize lead programs while others are monetized externally - 🌐 **Global expansion**: - Regional licensing enables reach into markets like China, LATAM, EU - 🔁 **Pipeline recycling**: - De-risk or recycle shelved programs --- ### 🔍 Licensing Structure Components |**Term**|**Explanation**| |---|---| |**Field of Use**|Disease area, indication, or platform application| |**Territory**|Country or region covered by the license| |**Exclusivity**|Exclusive vs. non-exclusive rights| |**Upfront Payment**|Non-refundable initial license fee| |**Milestone Payments**|Triggered by development, regulatory, or commercial events| |**Royalty Rate**|% of net sales paid to licensor| |**Sublicense Rights**|Can the licensee license it further? If yes, revenue-sharing terms apply| --- ### 🧠 Investor Lens As an investor or dealmaker, assess: - 🔬 Is the **underlying IP protected and freedom-to-operate clear**? - 💵 Is the **deal value** (upfront + milestones + royalties) aligned with asset potential? - 🧭 Does the licensee have **strong execution capability** in target territory? - 🔁 Is there **strategic optionality** (e.g., co-development, reacquisition rights)? - 📊 How does this license **affect overall company valuation and focus**? --- ### 🚀 Case Examples 1. **Argenx – Halozyme Enhanze® tech license** - Argenx licensed Enhanze® SC delivery tech to improve patient experience - ![[Pasted image 20250817214430.png]] - Result: faster SC formulation → better market access → milestone and royalty structure 2. **Innovent Biologics – Out-licensing to Lilly** - Chinese biotech Innovent out-licensed key oncology assets to Eli Lilly for China + ROW - Result: major upfront payment + long-term royalties; global credibility boost 3. **CRISPR Therapeutics – Out-licensing to Vertex** - CRISPR-based gene editing for sickle cell & beta-thalassemia - Vertex takes development lead → CRISPR gets funding + milestone share + royalty upside --- ## 🧾 Summary Table |**Feature**|**Out-Licensing Benefit**| |---|---| |**Monetization**|Early revenue without needing internal commercial team| |**Capital Efficiency**|Non-dilutive funding; milestone-based validation| |**Risk Management**|Transfers downstream risk to the licensee| |**Partner Leverage**|Taps into established regulatory/market expertise| |**Portfolio Focus**|Allows company to focus on most promising internal assets| --- > 🧬 As a biotech CEO: Out-licensing allows **strategic resource allocation**, fuels **non-dilutive runway**, and enhances pipeline visibility. > 💼 As an investor: It provides **valuation inflection** without equity dilution and enables **capital-light scalability**.